FDA approves Leqembi, first drug to slow Alzheimer’s progression
The Food and Drug Administration on Thursday granted full approval for the first time to an experimental Alzheimer's drug, triggering a process that could expand coverage of the $26,500 treatment to millions of patients. Why it matters: Eisai and Biogen's Leqembi was found to have modest success…
#biogen #teresaburacchio #fda #centersformedicare #medicaidservices #cms #medicare #georgevradenburg #joannepike #alzheimerassociation